Replies to post #330568 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

It’s a continuation patent grant, and adds/modifies claims from the earlier patent grant back in 2015, but the current patent grant was able to do this because it was filed in July 2015, and the prior grant was in August 2015, so the changes/continuation were granted in August 2020.

One, but certainly not all of the modifications in the claims involved the additional use of a metal chelator in the process.

“1. A method for differentiating human CD14+CD1a- monocytic dendritic cell precursors into immature dendritic cells having increased CD1a and having no CD14 on their cell surface, comprising:

a) contacting a cell population comprising human CD14+CD1a- monocytic dendritic cell precursors with an isolation medium supplemented with a metal chelator to provide non-activated human CD14+CD1a- monocytic dendritic cell precursors; and
b) contacting the non-activated human dendritic cell precursors in a culture vessel with a dendritic cell culture media supplemented with at least 1% animal or human protein, and an effective amount of granulocyte macrophage colony stimulating factor in the absence of additional cytokines for a time period sufficient for the human monocytic dendritic cell precursors to differentiate into immature dendritic cells having no expression of CD14 and having increased expression of CD1a on their cell surface.

2. The method according to claim 1, wherein the metal chelator comprises ethylenediamine tetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).”